Antibody response after a booster dose of SARS-CoV-2 vaccine in liver transplant recipients and those with chronic liver diseases.
JournalAnnals of Hepatology
MetadataShow full item record
AbstractBackground &Aims: Lower antibody (Ab) responses after SARS-CoV-2 vaccination have been reported in liver transplant (LT) recipients and those with chronic liver diseases (CLD). The role of a booster dose in those with poor responses to initial vaccination is not well defined. Methods: In this prospective study, we determined antibody (Ab) response to spike protein after a booster dose in LT recipients and those with chronic liver diseases (CLD) with and without cirrhosis after they had a poor response to an initial standard regimen. Results: Of the 80 patients enrolled, 45 had LT, and 35 had CLD (18 with cirrhosis). A booster dose was given at a median of 138.5 days after the completion of the standard regimen. After the booster dose, 58 (73%, 31 LT, 27 CLD) had good response (≥250 U/mL), and 22 (28%, 14 LT, and 8 CLD) had poor response (7 undetectable and 15 with low Ab levels). No patient had any serious adverse events. The antibody responses were lower in those who had undetectable Ab (80 U/mL) than those who had low levels of Ab (0.80-249 U/mL) after the standard vaccination regimen (42% vs.87%, p=0.0001). The antibody responses after homologous and heterologous booster doses were similar. Conclusions: We have shown that a booster dose will enhance Ab responses in LT recipients and those with CLD who had poor responses after an initial vaccine regimen.
Rights/TermsCopyright © 2022. Published by Elsevier España, S.L.U.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18375
- Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
- Authors: Thuluvath PJ, Robarts P, Chauhan M
- Issue date: 2021 Dec
- Humoral response to heterologous prime-booster vaccination in heart transplant recipients aged 18-70 years primed with a viral vector SARS-CoV-2 vaccine.
- Authors: Tanner R, Starr N, Perez-Garcia CN, Chan G, Dempsey E, Heffernan E, Lynch B, Hannan MM, Joyce E
- Issue date: 2022 Dec
- Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients.
- Authors: Toniutto P, Falleti E, Cmet S, Cussigh A, Veneto L, Bitetto D, Fornasiere E, Fumolo E, Fabris C, Sartor A, Peressutti R, Curcio F, Regattin L, Grillone L
- Issue date: 2022 Jul
- Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.
- Authors: Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D, Katchman E, Levi S, Houri I, Lubezky N, Shibolet O, Katchman H
- Issue date: 2021 Aug
- Mycophenolate mofetil decreases humoral responses to three doses of SARS-CoV-2 vaccine in liver transplant recipients.
- Authors: Meunier L, Sanavio M, Dumortier J, Meszaros M, Faure S, Ursic Bedoya J, Echenne M, Boillot O, Debourdeau A, Pageaux GP
- Issue date: 2022 Aug